MX2018014047A - Firmas de genes estromales para el diagnóstico y uso en inmunoterapia. - Google Patents
Firmas de genes estromales para el diagnóstico y uso en inmunoterapia.Info
- Publication number
- MX2018014047A MX2018014047A MX2018014047A MX2018014047A MX2018014047A MX 2018014047 A MX2018014047 A MX 2018014047A MX 2018014047 A MX2018014047 A MX 2018014047A MX 2018014047 A MX2018014047 A MX 2018014047A MX 2018014047 A MX2018014047 A MX 2018014047A
- Authority
- MX
- Mexico
- Prior art keywords
- immunotherapy
- individual
- gene signature
- stromal
- diagnosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96433—Serine endopeptidases (3.4.21)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La invención proporciona métodos para identificar individuos con una enfermedad o trastorno que tengan menos probabilidades de responder solo a la inmunoterapia, el método comprende determinar la presencia de una firma de genes estromales en una muestra del individuo, dicha firma comprende uno o más de FAP, FN1, MMP2, PDGFRB, o THY, en donde un aumento en el nivel de expresión del o los genes en la firma de genes estromales respecto a la mediana del nivel identifica a un individuo para el tratamiento con una inmunoterapia y con un antagonista estromal supresor. En algunos aspectos, la invención proporciona métodos para tratar a un individuo que manifiesta la firma de genes estromales. En otros aspectos, la invención proporciona kits para determinar la presencia de una firma de genes estromales en una muestra de un individuo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662337815P | 2016-05-17 | 2016-05-17 | |
PCT/US2017/032890 WO2017201036A1 (en) | 2016-05-17 | 2017-05-16 | Stromal gene signatures for diagnosis and use in immunotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018014047A true MX2018014047A (es) | 2019-06-20 |
Family
ID=59014732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018014047A MX2018014047A (es) | 2016-05-17 | 2017-05-16 | Firmas de genes estromales para el diagnóstico y uso en inmunoterapia. |
Country Status (11)
Country | Link |
---|---|
US (2) | US20190085087A1 (es) |
EP (1) | EP3458608A1 (es) |
JP (1) | JP7359547B2 (es) |
KR (1) | KR20190007026A (es) |
CN (1) | CN109312408B (es) |
AU (1) | AU2017268234A1 (es) |
CA (1) | CA3024465A1 (es) |
IL (1) | IL262862A (es) |
MX (1) | MX2018014047A (es) |
TW (1) | TW201809282A (es) |
WO (1) | WO2017201036A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019090263A1 (en) * | 2017-11-06 | 2019-05-09 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
WO2020005068A2 (en) * | 2018-06-29 | 2020-01-02 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Gene signatures and method for predicting response to pd-1 antagonists and ctla-4 antagonists, and combination thereof |
US20220112564A1 (en) * | 2019-02-14 | 2022-04-14 | Merck Sharp & Dohme Corp. | Gene expression based biomarker of tumor response to pd-1 antagonists |
CN110179976A (zh) * | 2019-05-22 | 2019-08-30 | 华中科技大学同济医学院附属同济医院 | 用于治疗癌症的组合药物制剂 |
WO2023010094A2 (en) * | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
CN114480639B (zh) * | 2021-12-24 | 2022-09-30 | 中国医学科学院北京协和医院 | 新靶点用于诊断和治疗垂体腺瘤 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5262319A (en) | 1985-04-19 | 1993-11-16 | Oncogene Science, Inc. | Method for obtaining bone marrow free of tumor cells using transforming growth factor β3 |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
CA2096441A1 (en) | 1990-11-16 | 1992-05-17 | Celtrix Pharmaceuticals, Inc. | Heterodimer of b-type transforming growth factors 2 and 3 |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
ES2241710T3 (es) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | Procedimiento para producir proteinas multivalentes de union a antigeno. |
EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
WO1993024640A2 (en) | 1992-06-04 | 1993-12-09 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
EP0754058B1 (en) | 1994-03-29 | 1999-11-03 | The Victoria University Of Manchester | Wound healing |
US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
WO2002061090A2 (en) | 2000-12-14 | 2002-08-08 | Genentech, Inc. | Prokaryotically produced antibodies and uses thereof |
ES2376454T3 (es) | 2000-12-22 | 2012-03-14 | Grad, Carole, Legal Representative Of Howard, Kaplan | Librer�?as de expresión en fago de fragmentos vh humanos. |
JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
EP1492568A1 (en) | 2002-04-08 | 2005-01-05 | SmithKline Beecham Corporation | Cancer treatment method comprising administration of an erb-family inhibitor and a raf and/or ras inhibitor |
ES2315664T3 (es) | 2003-06-30 | 2009-04-01 | Domantis Limited | Anticuerpos de dominio unico (dab) pegilados. |
EP1718677B1 (en) | 2003-12-19 | 2012-04-18 | Genentech, Inc. | Monovalent antibody fragments useful as therapeutics |
JP5128935B2 (ja) | 2004-03-31 | 2013-01-23 | ジェネンテック, インコーポレイテッド | ヒト化抗TGF−β抗体 |
PL3520815T3 (pl) | 2005-02-08 | 2022-04-11 | Genzyme Corporation | Przeciwciała przeciwko TGFBETA |
KR100978684B1 (ko) | 2005-04-22 | 2010-08-31 | 일라이 릴리 앤드 캄파니 | Tgf 베타 1 특이적 항체 |
CN100475965C (zh) | 2005-07-22 | 2009-04-08 | 上海高科联合生物技术研发有限公司 | 一种大肠杆菌高效外分泌表达溶葡萄球菌酶的方法 |
ATE545657T1 (de) | 2005-12-23 | 2012-03-15 | Lilly Co Eli | Tgf-beta antikörper |
PL2059533T3 (pl) | 2006-08-30 | 2013-04-30 | Genentech Inc | Przeciwciała wieloswoiste |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
PL2235064T3 (pl) | 2008-01-07 | 2016-06-30 | Amgen Inc | Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych |
KR20210060670A (ko) | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | 항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도 |
ES2894398T3 (es) | 2011-06-03 | 2022-02-14 | Xoma Technology Ltd | Anticuerpos específicos para TGF-beta |
WO2013134365A1 (en) | 2012-03-08 | 2013-09-12 | Ludwig Institute For Cancer Research Ltd | TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF |
KR20150090246A (ko) * | 2012-12-03 | 2015-08-05 | 알막 다이아그노스틱스 리미티드 | 암을 위한 분자 진단 테스트 |
SG11201507279XA (en) | 2013-03-11 | 2015-10-29 | Genzyme Corp | Engineered anti-tgf-beta antibodies and antigen-binding fragments |
US9402888B2 (en) * | 2013-03-14 | 2016-08-02 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treating cancer |
EP4356960A2 (en) * | 2013-03-15 | 2024-04-24 | F. Hoffmann-La Roche AG | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
US20150071910A1 (en) * | 2013-03-15 | 2015-03-12 | Genentech, Inc. | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
WO2014194293A1 (en) * | 2013-05-30 | 2014-12-04 | Amplimmune, Inc. | Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof |
JP6731346B2 (ja) * | 2014-02-10 | 2020-07-29 | メルク パテント ゲーエムベーハー | 標的TGFβ阻害 |
-
2017
- 2017-05-16 AU AU2017268234A patent/AU2017268234A1/en not_active Abandoned
- 2017-05-16 CN CN201780038362.1A patent/CN109312408B/zh active Active
- 2017-05-16 KR KR1020187036013A patent/KR20190007026A/ko not_active Application Discontinuation
- 2017-05-16 MX MX2018014047A patent/MX2018014047A/es unknown
- 2017-05-16 EP EP17728306.6A patent/EP3458608A1/en active Pending
- 2017-05-16 CA CA3024465A patent/CA3024465A1/en not_active Abandoned
- 2017-05-16 WO PCT/US2017/032890 patent/WO2017201036A1/en unknown
- 2017-05-16 JP JP2018560187A patent/JP7359547B2/ja active Active
- 2017-05-17 TW TW106116358A patent/TW201809282A/zh unknown
-
2018
- 2018-11-07 IL IL262862A patent/IL262862A/en unknown
- 2018-11-15 US US16/192,008 patent/US20190085087A1/en not_active Abandoned
-
2022
- 2022-08-12 US US17/886,809 patent/US20230151103A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20190007026A (ko) | 2019-01-21 |
CA3024465A1 (en) | 2017-11-23 |
WO2017201036A1 (en) | 2017-11-23 |
IL262862A (en) | 2018-12-31 |
EP3458608A1 (en) | 2019-03-27 |
CN109312408B (zh) | 2022-12-23 |
US20230151103A1 (en) | 2023-05-18 |
JP7359547B2 (ja) | 2023-10-11 |
US20190085087A1 (en) | 2019-03-21 |
AU2017268234A1 (en) | 2018-12-13 |
TW201809282A (zh) | 2018-03-16 |
JP2019523218A (ja) | 2019-08-22 |
CN109312408A (zh) | 2019-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018014047A (es) | Firmas de genes estromales para el diagnóstico y uso en inmunoterapia. | |
WO2015094995A3 (en) | Gene signature biomarkers of tumor response to pd-1 antagonists | |
MX2022006075A (es) | Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer. | |
MX2018008421A (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
WO2015094996A3 (en) | Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists | |
EP4180531A3 (en) | Nasal epithelium gene expression signature and classifier for the prediction of lung cancer | |
BR112017012222A2 (pt) | métodos para derivar um biomarcador de assinatura gênica e para tratar um paciente que tem um tumor, método e sistema para testar uma amostra de tumor removida de um paciente, e, kit. | |
EP3839510A3 (en) | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists | |
EA201992026A1 (ru) | Применение биомаркеров при идентификации пациентов, имеющих рак, которые будут характеризоваться наличием восприимчивости к лечению ингибитором prmt5 | |
MX2018012856A (es) | Metodos para determinar dipeptidil peptidasa 3 y metodos terapeuticos. | |
AR099856A1 (es) | Métodos para diagnosticar y tratar la enfermedad de intestino inflamado | |
AR080361A1 (es) | Identificacion, evaluacion y terapia de canceres con resistencia innata o adquirida a inhibidores de quinasa del linfoma anaplasico (alk) | |
WO2017042625A3 (en) | Molecular subtyping, prognosis and treatment of prostate cancer | |
NZ729773A (en) | Biomarkers for disease progression in melanoma | |
MX2020006388A (es) | Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea. | |
SG10201806729VA (en) | Novel assay to detect human periostin | |
GB2523211A8 (en) | MCT protein inhibitor-related prognostic and therapeutic methods | |
MX2016012278A (es) | Deteccion temprana de preeclampsia. | |
MX2020005657A (es) | Predictor de radioterapia de receptor de peptido usando un ensayo de expresion genica. | |
EA202090260A1 (ru) | Средства и способы для генотерапии aav у человека | |
MX2017003832A (es) | Metodo para la prediccion de sensibilidad a un tratamiento con un inhibidor de egfr. | |
EP3869198A3 (en) | Reagents and methods for breast cancer detection | |
WO2017103001A3 (en) | Diagnostic markers of immunosenescence and methods for determining the susceptibility to nosocomial infections | |
WO2020123880A3 (en) | Genomic rearrangements associated with prostate cancer and methods of using the same | |
EA201491780A1 (ru) | Мутанты c-raf, придающие резистентность к ингибиторам raf |